B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression
B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression
复制标题
DOI：
10.1016/j.ygyno.2007.03.035
复制
发表时间：
2007-08-01
影响因子：
4.7
通讯作者：
Diamandis, Eleftherios P.
中科院分区：
文献类型：
--
作者：
Simon, Iris;Katsaros, Dionyssios;Diamandis, Eleftherios P.
Objective.本研究描述了新的生物标志物B7-H4在卵巢癌组织、正常卵巢和良性卵巢肿瘤中的表达，并评估其与CA 125的关系。采用ELISA法检测了251例卵巢癌患者的卵巢组织裂解液中B7-H4和CA 125的水平。为了比较，检测了来自良性卵巢肿瘤患者（n=43）和正常卵巢患者（n=32）的卵巢组织。标志物浓度与CA 125表达、临床病理变量和患者预后相关。使用基于对照组中B7-H4或CAI 25浓度的第95百分位数的截止值，B7-H4在48%的I期癌症患者、55%的II期癌症患者和67%的晚期癌症患者中过表达。在31%的早期癌症患者中CAI 25升高。B7-H4在30例CA 125阴性的早期癌症患者的肿瘤中升高。B7-H4和CA 125的组合鉴定出56名早期癌症患者（65%）为阳性。标记物表达与临床结果的相关性表明，高B7-H4水平与不良预后相关。然而，当对其他临床病理变量进行调整时，这种影响并不显著。B7-H4在正常卵巢和良性肿瘤中表达较低，而一半的早期癌症和三分之二的晚期癌症过度表达B7-H4。这些数据与以前的观察结果一致，并支持进一步研究B7-H4单独或与CA 125联合检测早期卵巢癌。(C)2007年爱思唯尔公司All rights reserved.
Objective. This study characterizes the expression of the novel biomarker B7-H4 in ovarian cancer tissue, normal ovaries, and benign ovarian tumors, and evaluates its relationship to CA125.Methods. Ovarian tissue lysates from 251 patients with ovarian carcinoma were assessed for the levels of B7-H4 and CA125 by ELISA assays. For comparison, ovarian tissues from patients with benign ovarian tumors (n=43) and patients with normal ovaries (n=32) were tested. The marker concentrations were correlated with CA125 expression, clinicopathological variables, and patient outcome.Results. Using a cut-off based on the 95th percentile of B7-H4 or CAI 25 concentration in the control group, B7-H4 was over-expressed in 48% of patients with stage I cancer, 55% of patients with stage Il cancer, and 67% of patients with late stage cancer. CAI 25 was elevated in 31% patients with early stage cancer. B7-H4 was elevated in tumors of 30 patients with early stage cancer that were negative for CA125. The combination of B7-H4 and CA125 identified 56 early stage cancer patients (65%) as positive. Correlation of marker expression to clinical outcome showed that high B7-H4 levels were correlated with poor prognosis. However, the effect was not significant when outcome was adjusted for other clinicopathological variables.Conclusion. B7-H4 expression was low in normal ovaries and in benign tumors while half of early stage and two-thirds of late stage cancers over-expressed B7-H4. The data are consistent with previous observations and support further investigation of B7-H4 in the detection of early stage ovarian cancer either alone, or in combination with CA125. (C) 2007 Elsevier Inc. All rights reserved.